The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to https://sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.
Trademarks and/or registered trademarks mentioned herein are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries.
© 2020 DH Tech. Dev. Pte. Ltd.
SCIEX and EluciData to Offer an End-to-End Data Processing Pipeline for all Metabolomics Workflows in a Single Cloud-based Environment
Framingham, MA — SCIEX a global leader in life science analytical technologies, announces a co-marketing agreement with EluciData, a disruptive integrated Omics platform company providing tools for metabolomics data processing. This relationship will uniquely position SCIEX to address the major challenges faced by scientific researchers and allow them to efficiently process all of their metabolomics data from a diverse range of workflows. It will allow scientists to interpret these results in a biological context to further advance the fields of target identification and validation, as well as deeply characterize the underlying biology.
Under this agreement, EluciData and SCIEX will promote EluciData’s integrated Omics platform, called Polly™, in conjunction with SCIEX technologies, including TripleTOF®, X500R QTOF, and QTRAP®, as well as Differential Ion Mobility technology.
Polly™ is an end-to-end, vendor-neutral, integrated omics platform that standardizes and streamlines metabolomics data analysis workflows, as well as integrates various other forms of omics data, to better understand cellular phenotype. In addition to hosting and maintaining its proprietary workflows on a single cloud-based environment, EluciData allows its customers to post their own bespoke applications on Polly™, freeing up scientists’ time to focus their efforts on higher value activities. The result is an environment supporting customized omics processing pipelines, comprehensive bioinformatics analysis capabilities, real-time scientific collaboration, and project management.
Polly™ MetScape, a global metabolomics profiling data analysis workflow, is compatible with data acquired in SWATH® Acquisition mode, a data-independent acquisition (DIA) workflow that is now increasingly employed in untargeted metabolomics workflows. SWATH® Acquisition allows users to collect the MS and MS/MS of every detectable peak in their sample, thus creating a digital map of the metabolome.
The PollyPhi™ workflow enables hypothesis validation, allowing scientists to go from pathways to highlighting changes in enzyme function by analyzing the flow of labels through metabolites to validate hypotheses. Scientists can find the relative and kinetic flux from targeted and untargeted metabolomic data, acquired from MS and MS/MS methods, and using liquid and gaseous chromatographic methods.
“Manual mass spectroscopic flux analysis, and especially MS/MS analysis for our MIMOSA workflows, is incredibly time and thought demanding, as well as prone to user errors and limiting to our output,” said Dr. Richard Kibbey, Associate Professor of Medicine at Yale Medical School. “PollyPhi provides a soup-to-nuts analysis of our Differential Ion Mobility MS/MS data that greatly accelerates this process, freeing the bright minds and hands for more appropriate tasks. We use PollyPhi for analysis of data generated from our SCIEX QTRAP 5500 and TripleTOF 6600 instruments. It has transformed my lab.”
“Improving the efficiency of metabolomics workflows is critical if academic researchers and pharma customers want to advance precision medicine,“ said Mark Cafazzo, Director of Strategic Market Management at SCIEX. “The use of Polly with SCIEX metabolomics workflows accelerates their capabilities and empowers them to spend more time on the biology than on crunching data through fragmented software tools. By partnering with EluciData and applying Polly to SCIEX next-generation metabolomics solutions, we help scientists address the challenges they face every day.“
“We are very pleased to be working with SCIEX to provide scientists with effective solutions for metabolomics analysis,“ said Dr. Abhishek Jha, CEO of EluciData. “The combined capabilities of our two companies will enable scientists to extract superior biological insights from raw metabolomics data generated from various workflows.“
SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face. The company's global leadership and world-class service and support in the capillary electrophoresis and liquid chromatography-mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research.
With over 40 years of proven innovation, SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information, please visit sciex.com
For Research Use Only. Not for use in diagnostic procedures.
© 2019. SCIEX. The trademarks mentioned herein are the property of AB Sciex Pte. Ltd. (or their respective owners) in the U.S. and/or certain other countries. AB SCIEX™ is being used under license.
EluciData’s mission is to transform the way data is used to drive decisions in R&D labs. We combine a proprietary platform with optional, on-demand high-value bioinformatics services for biological target identification and validation, pathway elucidation, cellular phenotype analysis, and biomarker identification.
We have created Polly™, an end-to-end, vendor-neutral, cloud-based platform that standardizes and streamlines omics data analysis workflows, as well as integrates different forms of omics data to understand cellular phenotype. The Polly™ system analyzes and integrates data across metabolomics, genomics, transcriptomics, and proteomics, providing enhanced analysis on the underlying biology of a particular cell or system. Our on-demand service offerings include collecting, curating, and analyzing biological data as well as creating custom software product offerings to assist clients in their efforts to better identify, validate, and develop biological targets, pathways, and biomarkers, speeding development of an organization's therapeutics assets. Further information on EluciData solutions can be found at www.elucidata.io.
Program Manager, Brand, Public Relations and Social Media, SCIEX
+1 (508) 383-7163
M: +1 (508) 782-9484
A new password has been sent to your email.
You have added a user.
Unfortunately the serial number you provided shows as inactive in our database. Would you like to submit the case anyway?
This serial number could not be found. Would you like to submit the case anyway?
Your password has been updated.
Your account is now created.
A verification link has been sent to your email.
A new password has been sent to your email.
Your insturment has been removed.
Your privacy settings are now updated.
Unfortunately the serial number you provided shows as inactive in our database. Please open a support case here if you require more assistance.
Software has already been registered to another instrument. Please check your AID and try again.
If you want to change the License Key to another instrument, please submit a new case.
Software has already been registered to the instrument selected.
Please check your instrument's software by going to the Instruments page and selecting the instrument in your "My Instruments" section. Here you will see a Software tab where you can view your instrument's software information.
You can also go to the Registered Software page to view software associated with your instrument(s).
If you are not finding what you are looking for, please submit a new case.